Appili Therapeutics (OTCMKTS:APLIF) Issues Earnings Results

Appili Therapeutics (OTCMKTS:APLIF) released its quarterly earnings data on Tuesday. The company reported ($0.01) EPS for the quarter, hitting analysts’ consensus estimates of ($0.01), reports. The company had revenue of $0.01 million for the quarter.

Appili Therapeutics Stock Performance

APLIF opened at $0.03 on Thursday. Appili Therapeutics has a fifty-two week low of $0.02 and a fifty-two week high of $0.08. The company has a market capitalization of $3.13 million, a P/E ratio of -0.86 and a beta of -0.53. The stock has a fifty day moving average of $0.03 and a 200-day moving average of $0.03.

About Appili Therapeutics

Appili Therapeutics Inc, a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis.